Sundar S K, Ablashi D V, Kamaraju L S, Levine P H, Faggioni A, Armstrong G R, Pearson G R, Krueger G R, Hewetson J F, Bertram G, Sesterhenn K, Menezes J
Int J Cancer. 1982 Apr 15;29(4):407-12. doi: 10.1002/ijc.2910290408.
A unique association of Epstein-Barr virus (EBV) with the undifferentiated nasopharyngeal carcinoma (NPC) is a well acknowledged phenomenon. We report here the detection of a factor present in the sera of NPC patients which inhibits the blastogenic response of lymphocytes from EBV seropositive individuals to EB virions or soluble antigens. This lymphocyte-stimulation inhibitor (LSI) was found to be associated with the IgA fraction of the serum immunoglobulins. No inhibitory activity was detected in the sera and their immunoglobulin fractions from healthy (both EBV-seropositive and seronegative) individuals and patients with other carcinomas of the head and neck region. Interestingly, the IgA-LSI was absent in the sera of NPC patients who were successfully treated and remained in remission, while it was readily detectable in the sera of NPC patients in relapse, LSI-positive IgA fractions did not inhibit mitogenic response of lymphocytes to phytohemagglutinin. Taken together, the data presented suggest that LSI is a specific inhibitor of the response of sensitized lymphocytes to EBV antigens and that it may indeed represent a marker of great clinical significance regarding undifferentiated nasopharyngeal carcinoma, particularly for its prognosis.
爱泼斯坦-巴尔病毒（EBV）与未分化鼻咽癌（NPC）之间存在独特关联，这是一个广为人知的现象。我们在此报告，在NPC患者血清中检测到一种因子，它能抑制EBV血清学阳性个体的淋巴细胞对EB病毒颗粒或可溶性抗原的增殖反应。这种淋巴细胞刺激抑制剂（LSI）被发现与血清免疫球蛋白的IgA组分相关。在健康人（包括EBV血清学阳性和阴性）以及头颈部其他癌症患者的血清及其免疫球蛋白组分中未检测到抑制活性。有趣的是，成功治疗且仍处于缓解期的NPC患者血清中不存在IgA-LSI，而在复发的NPC患者血清中很容易检测到。LSI阳性的IgA组分并不抑制淋巴细胞对植物血凝素的促有丝分裂反应。综上所述，所呈现的数据表明LSI是致敏淋巴细胞对EBV抗原反应的特异性抑制剂，并且它可能确实代表了与未分化鼻咽癌具有重大临床意义的标志物，特别是对于其预后而言。
